Metraipolis › archive › dc_5eaa8d96aeaa

Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion — Europe PMC PMID:41107611

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41107611
DOI
10.1007/s00415-[numero omesso]-0
License (as archived)
solo-consultazione
Archived
2026-11-09T06:20:10.156Z
SHA-256 of the archived text
b54743a12a6aba89868e66c096981b8904604dbaa1fd183a309314f2b1c3aa0d
Stable URL of this page
https://metraipolis.com/documento/dc_5eaa8d96aeaa

How to cite

Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion — Europe PMC PMID:41107611 — Europe PMC (en), https://europepmc.org/article/MED/41107611 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5eaa8d96aeaa (Metraipolis archive dc_5eaa8d96aeaa, sha256 b54743a12a6aba89868e66c096981b8904604dbaa1fd183a309314f2b1c3aa0d)
BibTeX
@misc{dc5eaa8d96aeaa,
  title = {Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion — Europe PMC PMID:41107611},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41107611},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5eaa8d96aeaa; sha256 b54743a12a6aba89868e66c096981b8904604dbaa1fd183a309314f2b1c3aa0d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41107611. Agents can read the archived copy with the MCP tool read_document.